Lanreotide 120 mg every 28 days (LAN) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (panNET) in routine clinical practice in Iberia

被引：0
|
作者：
Alonso-Gordoa, T. [1 ]
Capdevila, J. [2 ]
Gonzalez, E. [3 ]
Teule, A. [4 ]
Anido, U. [5 ]
Segura, A. [6 ]
Bolanos, M. [7 ]
Hernando, J. [2 ]
Lorenzo, I [8 ]
Grandoulier, A. S. [9 ]
de La Cruz, G. [10 ]
机构：
[1] Hosp Univ Ramon y Cajal, Madrid, Spain
[2] Hosp Univ Vall dHebron, Barcelona, Spain
[3] Hosp Univ Virgen de las Nieves, Granada, Spain
[4] Hosp ICO Bellvitge, Barcelona, Spain
[5] Hosp Prov Conxo, Santiago De Compostela, Spain
[6] Hosp Univ & Politecn La Fe, Valencia, Spain
[7] Hosp Univ Juan Ramon Jimenez, Huelva, Spain
[8] Hosp Alvaro Cunqueiro, Vigo, Spain
[9] Ipsen Pharma, Boulogne, France
[10] Ipsen Pharma, Barcelona, Spain
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2022年 / 34卷
关键词：
net; pancreas; lanreotide; clinical practice;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
I02
引用
收藏
页码：164 / 164
页数：1
相关论文
共 25 条
  • [21] Real World Molecular Testing in Patients with EGFR Mutation-Positive (EGFRM plus ) Locally Advanced or Metastatic NSCLC in Routine Practice in Germany - Interim Results of The Clinical Registry Panorama
    Schuette, Wolfgang
    Schumann, Christian
    Buettner, Reinhard
    Deppertnann, Karl-Matthias
    Reinmuth, Niels
    Thomas, Michael
    Wroblewski, Mark
    Griesinger, Frank
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 118 - 118
  • [22] Design of a phase 3, international multicenter, prospective, randomized, double-blind, placebo controlled study assessing the efficacy and safety of lanreotide depot 120 mg in patients with well-differentiated, advanced typical and atypical lung neuroendocrine tumors (NETs)
    Reidy-Lagunes, Diane
    Wolin, Edward M.
    Lowenthal, Susan Pitman
    Cox, David
    Kulke, Matthew H.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S31 - S31
  • [23] Long-term survival and clinical efficacy in patients with advanced pancreatic and small bowel metastatic neuroendocrine tumors (GEP-NET) after IV 90Y DOTATATE.
    Rogowski, Wojciech
    Wachula, Ewa
    Zok, Jolanta
    Lewczuk, Anna
    Cwikla, Jaroslaw
    Wysocki, Piotr
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Phase I, open-label, dose-escalating clinical and pharmacokinetic study of the novel antimicrotubulin agent PM060184 administered over 10 minutes on days 1-3 and 15-17 every 28 days to patients with advanced malignant solid tumors
    Hidalgo, M.
    Boni, V.
    Tolcher, A.
    Smith, L.
    Cubillo, A.
    Rasco, D.
    Calvo, E.
    Amaya, A.
    Ordonez, E.
    Patnaik, A.
    Cerda, S.
    Coronado, C.
    Fudio, S.
    Miguel-Lillo, B.
    Prados, R.
    Ortega, O.
    Soto-Matos, A.
    Papadopoulos, K. P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S74 - S74
  • [25] Is Next-Generation Sequencing (NGS) Ready for Routine Clinical Practice in Advanced Well Differentiated Pancreatic Neuroendocrine Tumors (WD panNETs): Results of a Prospective Study Utilizing MSK-IMPACT (Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets)
    Raj, Nitya
    Soumerai, Tara
    Valentino, Emily
    Reidy-Lagunes, Diane
    PANCREAS, 2016, 45 (03) : 468 - 469
123